ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer
The addition of nimotuzumab to gemcitabine (Gemzar) increases overall survival in patients with K-Ras wild-type advanced pancreatic…
Browsing: ASCO
ASCO 2022: Three-year follow up results from the TheraP study for metastatic prostate cancer
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year…
ASCO 2022: The updated results from the ENZAMET clinical trial
The Australian-led clinical trial ENZAMET has shown that the addition of hormone therapy with a…
ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein
A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise…
ASCO 2022: ctDNA may help identify the need for adjuvant therapy in stage II colon cancer
In patients with stage II colon cancer where cancer DNA was not present in the…
ASCO 2022: Lung cancer therapy could help patients live longer
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug…
ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas
Two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to…
ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy
Based on guidance from biomarker screening, patients who are 55 years of age and older…
ASCO 2022: Gut microbiome signatures associated with immunotherapy response in glioblastoma
Immunotherapy has had limited success so far against glioblastoma, the most common and aggressive form…
ASCO 2022: Gut microbiome associated with increased immune cell infiltration in the tumour microenvironment and response to immunotherapy across cancer types
Recent research led by MD Anderson identified associations between neoadjuvant immune checkpoint blockade responses and B…